What’s Ahead for ZIOPHARM Oncology Inc. (ZIOP) After Today’s Huge Increase?

September 17, 2017 - By Linda Rogers

The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a huge mover today! The stock increased 3.67% or $0.22 on September 15, reaching $6.21. About 1.99 million shares traded or 73.04% up from the average. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has risen 1.75% since September 17, 2016 and is uptrending. It has underperformed by 14.95% the S&P500.
The move comes after 9 months positive chart setup for the $881.59 million company. It was reported on Sep, 17 by Barchart.com. We have $6.77 PT which if reached, will make NASDAQ:ZIOP worth $79.34M more.

Wall Street await ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to release earnings on November, 8. Analysts forecast EPS of $-0.13, down exactly $0.02 or 18.18 % from 2014’s $-0.11 EPS. After posting $-0.13 EPS for the previous quarter, ZIOPHARM Oncology Inc.’s analysts now forecast 0.00 % EPS growth.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 6 analyst reports since December 4, 2015 according to SRatingsIntel. Mizuho maintained ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rating on Wednesday, May 11. Mizuho has “Neutral” rating and $7 target. The stock has “Market Perform” rating by Wells Fargo on Wednesday, August 10. Mizuho maintained ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rating on Monday, January 25. Mizuho has “Neutral” rating and $6 target. The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) earned “Market Perform” rating by Raymond James on Thursday, June 2. The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) earned “Underperform” rating by Wells Fargo on Friday, December 4.

Another recent and important ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) news was published by Zacks.com which published an article titled: “Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock August 28 …” on August 28, 2017.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The company has market cap of $881.59 million. The Firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral therapies for the treatment of cancer and graft-versus-host-disease. It currently has negative earnings. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System expression platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.